¼¼°èÀÇ ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀå
Influenza Vaccines
»óǰÄÚµå : 1774948
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 554 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,239,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,719,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°è ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀåÀº 2030³â±îÁö 103¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 74¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ÀÎÇ÷翣ÀÚ ¹é½Å ¼¼°è ½ÃÀåÀº 2024-2030³â°£ CAGR 5.8%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 103¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ºÒȰ¼ºÈ­ 󸮴 CAGR 6.8%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á±îÁö 74¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¾àµ¶»ý±Õ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 3.7%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 20¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 9.4%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹Ãø

¹Ì±¹ÀÇ ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀåÀº 2024³â¿¡ 20¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 21¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 9.4%·Î ÃßÁ¤µË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 2.8%¿Í 5.8%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 3.8%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

ÀÎÇ÷翣ÀÚ ¹é½Å: ¹ßÀü, ½ÃÀå µ¿Çâ, ¼¼°è ¿µÇâ·Â

µ¶°¨ ¹é½Å ½ÃÀåÀº Áö³­ 10³â°£ °èÀý¼º µ¶°¨ À¯Çà¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í È¿°úÀûÀÎ ¿¹¹æÁ¢Á¾ ÇÁ·Î±×·¥¿¡ ´ëÇÑ Çʿ伺ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Å©°Ô ¼ºÀåÇØ ¿Ô½À´Ï´Ù. Àü ¼¼°è Á¤ºÎ¿Í ÀÇ·á ±â°üÀº ³ëÀÎ, ¾î¸°ÀÌ, ¸¸¼ºÁúȯÀÚ µî °íÀ§Ç豺ÀÇ ÀÔ¿øÀ» ÁÙÀ̰í ÇÕº´ÁõÀ» ¿¹¹æÇϱâ À§ÇØ µ¶°¨ ¿¹¹æÁ¢Á¾ Ä·ÆäÀÎÀÇ ¿ì¼±¼øÀ§¸¦ Á¤Çϰí ÀÖ½À´Ï´Ù. ½ÅÁ¾ ÀÎÇ÷翣ÀÚÀÇ ÃâÇöÀº ¹é½ÅÀÇ Á¤±âÀûÀÎ ¾÷µ¥ÀÌÆ®¿Í Àü ¼¼°è °¨½Ã Ȱµ¿ÀÇ Á߿伺À» ´õ¿í °­Á¶Çϰí ÀÖ½À´Ï´Ù.

4°¡ ¹é½Å°ú ¼¼Æ÷ ±â¹Ý Á¦Á¦ °³¹ß µî ¹é½Å ±â¼úÀÇ ¹ßÀüÀ¸·Î µ¶°¨ ¹é½ÅÀÇ È¿´É°ú Á¢±Ù¼ºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ÀüÅëÀûÀÎ °è¶õ ±â¹Ý Á¦Á¶ ¹æ¹ýÀº ÇöÀçµµ ³Î¸® »ç¿ëµÇ°í ÀÖÁö¸¸, ÀçÁ¶ÇÕ DNA ±â¼ú°ú °°Àº »õ·Î¿î Á¢±Ù¹ýÀ¸·Î Á¡Â÷ º¸¿ÏµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº ¹é½Å »ý»ê ±â°£À» ´ÜÃàÇÏ°í ±ÕÁÖ¸¦ °­È­ÇÏ¿© ¹é½ÅÀÇ È¿´ÉÀ» Çâ»ó½Ãų ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ, µ¶°¨ ¿¹¹æ°ú ´Ù¸¥ ¿¹¹æÁ¢Á¾À» ÅëÇÕÇÑ È¥ÇÕ ¹é½ÅÀÇ µîÀåÀº ƯÈ÷ ¼Ò¾Æ ¹× ³ëÀÎ ÀÇ·á ºÐ¾ß¿¡¼­ Àα⸦ ²ø°í ÀÖ½À´Ï´Ù.

±â¼ú Çõ½ÅÀº ¾î¶»°Ô µ¶°¨ ¹é½Å °³¹ßÀ» °­È­Çϴ°¡?

µ¶°¨ ¹é½Å °³¹ßÀÇ °¡Àå µÎµå·¯Áø ¹ßÀü Áß Çϳª´Â ¼¼Æ÷ ±â¹Ý ¹é½Å°ú À¯ÀüÀÚ ÀçÁ¶ÇÕ ¹é½ÅÀ¸·ÎÀÇ ÀüȯÀÔ´Ï´Ù. »ý»ê¿¡ ¼ö°³¿ùÀÌ °É¸®°í Ç׿ø µå¸®ÇÁÆ®¿¡ ÀÇÇØ È¿´ÉÀÌ ¶³¾îÁú ¼ö ÀÖ´Â ³­ÀÚ ±â¹Ý ¹é½Å°ú ´Þ¸®, ¼¼Æ÷ ±â¹Ý »ý»êÀº ´õ ºü¸£°í È®Àå °¡´ÉÇϸç Àϰü¼º ÀÖ´Â ´ë¾ÈÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ¹æ¹ýÀº ³­ÀÚ°¡ ÇÊ¿äÇÏÁö ¾ÊÀ¸¸ç, ¹é½ÅÀÇ È¿´ÉÀ» ¼Õ»ó½Ãų ¼ö ÀÖ´Â µ¹¿¬º¯ÀÌÀÇ À§Çèµµ ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù.

¶Ç ´Ù¸¥ Áß¿äÇÑ Çõ½ÅÀº º¸ÆíÀûÀÎ µ¶°¨ ¹é½ÅÀÇ °³¹ßÀÔ´Ï´Ù. ¿¬±¸ÆÀÀº µ¶°¨ ¹ÙÀÌ·¯½ºÀÇ º¸Á¸µÈ ¿µ¿ªÀ» Ç¥ÀûÀ¸·Î ÇÏ´Â ±¤¹üÀ§ÇÑ ½ºÆåÆ®·³ ¹é½ÅÀ» ¿¬±¸Çϰí ÀÖÀ¸¸ç, ¿©·¯ ±ÕÁÖ¿¡ ´ëÇÑ Àå±âÀûÀÎ ¸é¿ª·ÂÀ» È®º¸ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù. ÀÌ Á¢±Ù¹ýÀº ¸Å³â ¹é½Å Á¢Á¾ÀÇ Çʿ伺À» ÁÙÀ̰í Àü¹ÝÀûÀÎ ¿¹¹æ È¿°ú¸¦ Çâ»ó½ÃÅ´À¸·Î½á µ¶°¨ ¿¹¹æ¿¡ Çõ¸íÀ» °¡Á®¿Ã ¼ö ÀÖ½À´Ï´Ù. ¸¸´É ¹é½Å¿¡ ´ëÇÑ ÀÓ»ó½ÃÇèÀº ÇöÀç ÁøÇà ÁßÀ̸ç, °¡±î¿î ½ÃÀÏ ³»¿¡ ȹ±âÀûÀÎ ÁøÀüÀ» ÀÌ·ê ¼ö ÀÖ´Â À¯¸ÁÇÑ °á°ú¸¦ º¸¿©ÁÖ°í ÀÖ½À´Ï´Ù.

mRNA ±â¼úÀ» µ¶°¨ ¹é½Å »ý»ê¿¡ ÅëÇÕÇÏ´Â °Íµµ °ÔÀÓ Ã¼ÀÎÀú·Î, mRNA¸¦ ÀÌ¿ëÇÑ Äڷγª19 ¹é½ÅÀÇ ¼º°ø¿¡ ÈûÀÔ¾î Á¦¾àȸ»çµéÀº ÇöÀç ÀÌ ±â¼úÀ» Ȱ¿ëÇÏ¿© º¸´Ù ÀûÀÀ·ÂÀÌ ¶Ù¾î³ª°í ½Å¼ÓÇÏ°Ô ¹èÆ÷ÇÒ ¼ö ÀÖ´Â µ¶°¨ ¹é½ÅÀ» °³¹ßÇϰí ÀÖ½À´Ï´Ù.

µ¶°¨ ¹é½Å À¯ÅëÀÇ °úÁ¦¿Í ±ÔÁ¦ À¯ÀÇ»çÇ×Àº?

µ¶°¨ ¹é½Å ½ÃÀåÀº Å« ÁøÀü¿¡µµ ºÒ±¸Çϰí Á¦Á¶ÀÇ È®À强, À¯Åë ¹°·ù, ¹é½Å Á¢Á¾¿¡ ´ëÇÑ ¸Á¼³ÀÓ µîÀÇ ¹®Á¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. °¡Àå Å« Àå¾Ö¹° Áß Çϳª´Â µ¶°¨ ¹ÙÀÌ·¯½ºÀÇ º¯À̰¡ ¿¹ÃøÇÒ ¼ö ¾ø½À´Ï´Ù´Â Á¡À¸·Î, ÁøÈ­ÇÏ´Â ±ÕÁÖ¿¡ ´ëÀÀÇϱâ À§Çؼ­´Â ¸Å³â ÀçÁ¦ÇüÈ­ ¹× ´ë·® »ý»êÀÌ ÇÊ¿äÇÕ´Ï´Ù. ¹é½ÅÀÇ È¿´ÉÀº °èÀý¿¡ µû¶ó ´Þ¶óÁú ¼ö ÀÖÀ¸¸ç, ÀÌ´Â »çȸÀû ½Å·Ú¿Í ¹é½Å º¸±Þ¿¡ ¾î·Á¿òÀ» ÃÊ·¡Çϰí ÀÖ½À´Ï´Ù.

±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ ÀýÂ÷µµ ¹é½ÅÀÇ °¡¿ë¼º¿¡ ¿µÇâÀ» ¹ÌĨ´Ï´Ù. µ¶°¨ ¹é½ÅÀº ¹èÆ÷ Àü¿¡ ¾ö°ÝÇÑ ÀÓ»ó½ÃÇè°ú ¾ÈÀü¼º Æò°¡¸¦ °ÅÃÄ¾ß ÇÕ´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)¿Í ¹Ì±¹ ½ÄǰÀǾ౹(FDA)À» Æ÷ÇÔÇÑ ¼¼°è º¸°Ç ±â°üÀº ±ÕÁÖ ¼±ÅÃ, Á¦Á¶ ¹æ¹ý, À¯Åë ÇÁ·¹ÀÓ¿öÅ©¿¡ ´ëÇÑ ÁöħÀ» ¸¶·ÃÇϰí ÀÖ½À´Ï´Ù. ¾ö°ÝÇÑ ¾ÈÀü ±âÁØÀ» À¯ÁöÇϸ鼭 Àû½Ã¿¡ ¹é½ÅÀ» ¹èÆ÷ÇÏ´Â °ÍÀº ¿©ÀüÈ÷ Áß¿äÇÑ ±ÕÇü °¨°¢ÀÌ ÇÊ¿äÇÕ´Ï´Ù.

¶Ç ´Ù¸¥ °úÁ¦´Â ƯÈ÷ Àú¼ÒµæÃþ°ú °³¹ßµµ»ó±¹¿¡¼­ ¹é½ÅÀ» ½±°Ô ±¸ÇÒ ¼ö ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. °ø±Þ¸Á Á¦¾à, ³ÃÀå º¸°üÀÇ Çʿ伺, À¯Åë ºñ¿ë µîÀÌ Áý´Ü ¿¹¹æÁ¢Á¾À» ¹æÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. Ãë¾à Áö¿ªÀÇ µ¶°¨ ¹é½Å Á¢±Ù¼ºÀ» °³¼±Çϱâ À§Çؼ­´Â Á¤ºÎ, ¹é½Å Á¦Á¶¾÷ü, ºñ¿µ¸® ´Üü °£ÀÇ ±¹Á¦ Çù·ÂÀÌ ÇʼöÀûÀ̸ç, WHOÀÇ ¼¼°è ÀÎÇ÷翣ÀÚ µ¿Çâ ¸ð´ÏÅ͸µ ¹× ´ëÀÀ ½Ã½ºÅÛ(GISRS)°ú °°Àº ³ë·ÂÀº ÀÎÇ÷翣ÀÚ µ¿ÇâÀ» ¸ð´ÏÅ͸µÇÏ°í ¹é½ÅÀÇ Àû½Ã ¾÷µ¥ÀÌÆ®¸¦ ÃËÁøÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¹é½ÅÀÇ Àû½Ã ¾÷µ¥ÀÌÆ®¸¦ ÃËÁøÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.

µ¶°¨ ¹é½Å ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

µ¶°¨ ¹é½Å ½ÃÀåÀÇ ¼ºÀåÀº ¹é½Å ±â¼ú ¹ßÀü, ¿¹¹æÁ¢Á¾ ÀÎ½Ä °³¼±, Á¤ºÎ ÁÖµµÀÇ ¿¹¹æÁ¢Á¾ ÇÁ·Î±×·¥ µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ÁÖ¿ä ¿äÀÎ Áß Çϳª´Â mRNA ¹é½Å, À¯ÀüÀÚ ÀçÁ¶ÇÕ ¹é½Å, ¸¸´É ¹é½Å µî È¿´ÉÀ» Çâ»ó½ÃŰ°í »õ·Î¿î º¯Á¾¿¡ ºü¸£°Ô ÀûÀÀÇÒ ¼ö ÀÖ´Â Â÷¼¼´ë µ¶°¨ ¹é½ÅÀÇ Áö¼ÓÀûÀÎ °³¹ßÀÔ´Ï´Ù.

Á¤ºÎ Àڱݰú ¹Î°ü ÆÄÆ®³Ê½Ê Áõ°¡µµ ½ÃÀå È®´ë¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. ¸¹Àº ±¹°¡¿¡¼­ ±¹°¡ ¿¹¹æÁ¢Á¾ ÇÁ·Î±×·¥À» ½ÃÇàÇϰí ÀÖÀ¸¸ç, ¹é½Å Á¢Á¾·üÀ» ³ôÀ̱â À§ÇØ ¹é½Å ºñ¿ëÀ» º¸Á¶Çϰí ÀÖ½À´Ï´Ù. µ¶°¨ ¿¹¹æÁ¢Á¾À» Á¦°øÇÏ´Â ¾à±¹ ¹× ¼Ò¸Å Ŭ¸®´ÐÀÇ ¿ªÇÒÀÌ Áõ°¡ÇÔ¿¡ µû¶ó, ƯÈ÷ ¼±Áø±¹¿¡¼­´Â ¹é½Å¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ ´õ¿í Çâ»óµÇ°í ÀÖ½À´Ï´Ù.

¶ÇÇÑ, Àü ¼¼°èÀûÀ¸·Î Àü¿°º´¿¡ ´ëÇÑ ´ëºñ°¡ °­Á¶µÇ¸é¼­ µ¶°¨ ¹é½Å Á¢Á¾ÀÇ Á߿伺ÀÌ ³ô¾ÆÁö°í ÀÖÀ¸¸ç, Äڷγª19 ÆÒµ¥¹ÍÀº °­·ÂÇÑ È£Èí±â Áúȯ ¿¹¹æ Á¶Ä¡ÀÇ Çʿ伺À» °­Á¶ÇÏ°í µ¶°¨ ¹é½Å ¿¬±¸ ¹× °³¹ß¿¡ ´ëÇÑ ÅõÀÚ¸¦ È®´ëÇÏ´Â °è±â°¡ µÇ¾ú½À´Ï´Ù. ÀÇ·á ½Ã½ºÅÛÀÌ ¿¹¹æ ÀǷḦ ¿ì¼±½ÃÇÔ¿¡ µû¶ó µ¶°¨ ¹é½Å¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ¿© ÇâÈÄ ¸î ³â µ¿¾È ½ÃÀå ±Ëµµ¸¦ Çü¼ºÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ºÎ¹®

¹é½Å À¯Çü(ºÒȰ¼ºÈ­, ¾àµ¶»ý);ÀûÀÀÁõ(4°¡, 3°¡);±â¼ú(°è¶õ ±â¹Ý, ¼¼Æ÷ ±â¹Ý);ÀÎÇ÷翣ÀÚ À¯Çü(°èÀý¼º, ÆÒµ¥¹Í);¿¬·ÉÃþ(¼Ò¾Æ°ú, ¼ºÀÎ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹

AI ÅëÇÕ

¿ì¸®´Â °ËÁõ µÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM³ª ¾÷°èº° SLM Äõ¸®¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ´ë·® ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Influenza Vaccines Market to Reach US$10.3 Billion by 2030

The global market for Influenza Vaccines estimated at US$7.4 Billion in the year 2024, is expected to reach US$10.3 Billion by 2030, growing at a CAGR of 5.8% over the analysis period 2024-2030. Inactivated, one of the segments analyzed in the report, is expected to record a 6.8% CAGR and reach US$7.4 Billion by the end of the analysis period. Growth in the Live attenuated segment is estimated at 3.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.0 Billion While China is Forecast to Grow at 9.4% CAGR

The Influenza Vaccines market in the U.S. is estimated at US$2.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.1 Billion by the year 2030 trailing a CAGR of 9.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.8% and 5.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.8% CAGR.

Global Influenza Vaccine Market - Key Trends & Drivers Summarized

Influenza Vaccines: Advancements, Market Trends, and Global Impact

The influenza vaccine market has seen significant growth over the past decade, driven by increasing awareness of seasonal influenza outbreaks and the need for effective immunization programs. Governments and healthcare organizations worldwide have prioritized flu vaccination campaigns to reduce hospitalizations and prevent complications among high-risk populations, including the elderly, children, and individuals with chronic health conditions. The emergence of new influenza strains has further underscored the importance of regular vaccine updates and global surveillance efforts.

Advancements in vaccine technology, including the development of quadrivalent vaccines and cell-based formulations, have improved the efficacy and availability of influenza vaccines. Traditional egg-based production methods, while still widely used, are gradually being supplemented by newer approaches such as recombinant DNA technology. These innovations allow for faster production timelines and enhanced strain matching, improving vaccine effectiveness. Additionally, the rise of combination vaccines that integrate flu protection with other immunizations is gaining traction, particularly in pediatric and geriatric healthcare sectors.

How Are Technological Innovations Enhancing Influenza Vaccine Development?

One of the most notable advancements in influenza vaccine development is the shift towards cell-based and recombinant vaccines. Unlike egg-based vaccines, which require months to produce and can be less effective due to antigenic drift, cell-based manufacturing offers a faster, more scalable, and consistent alternative. This method eliminates the need for eggs and reduces the risk of mutations that could compromise vaccine effectiveness.

Another key innovation is the development of universal influenza vaccines. Researchers are exploring broad-spectrum vaccines that target conserved regions of the influenza virus, aiming to provide long-term immunity against multiple strains. This approach could revolutionize flu prevention by reducing the need for annual vaccinations and improving overall protection. Clinical trials for universal vaccines are underway, with promising results indicating potential breakthroughs in the near future.

The integration of mRNA technology into influenza vaccine production is also a game-changer. Following the success of mRNA COVID-19 vaccines, pharmaceutical companies are now leveraging this technology to develop more adaptive and rapidly deployable flu vaccines. mRNA-based influenza vaccines could enable real-time strain updates and enhance immune responses, making them a key focus for future immunization strategies.

What Are the Challenges and Regulatory Considerations in Influenza Vaccine Distribution?

Despite significant progress, the influenza vaccine market faces challenges related to production scalability, distribution logistics, and vaccine hesitancy. One major hurdle is the unpredictability of influenza virus mutations, requiring annual reformulation and mass production to keep up with evolving strains. The effectiveness of vaccines can vary from season to season, creating challenges in public confidence and vaccine adoption.

Regulatory approval processes also impact vaccine availability. Influenza vaccines must undergo rigorous clinical trials and safety evaluations before they can be distributed. Global health agencies, including the World Health Organization (WHO) and the U.S. Food and Drug Administration (FDA), establish guidelines for strain selection, manufacturing practices, and distribution frameworks. Ensuring timely vaccine rollout while maintaining stringent safety standards remains a critical balancing act.

Another challenge is vaccine accessibility, particularly in low-income and developing regions. Supply chain limitations, cold storage requirements, and distribution costs can hinder mass immunization efforts. International collaborations between governments, vaccine manufacturers, and non-profit organizations are essential to improving access to flu vaccines in underprivileged areas. Efforts such as the WHO’s Global Influenza Surveillance and Response System (GISRS) play a crucial role in monitoring flu trends and facilitating timely vaccine updates.

What Is Driving the Growth of the Influenza Vaccine Market?

The growth in the influenza vaccine market is driven by several factors, including advancements in vaccine technology, increasing immunization awareness, and government-led vaccination programs. One of the primary drivers is the continuous development of next-generation flu vaccines, including mRNA, recombinant, and universal vaccines, which offer improved efficacy and faster adaptability to emerging strains.

The rise in government funding and public-private partnerships has also fueled market expansion. Many countries have implemented national immunization programs and subsidized vaccine costs to encourage higher vaccination rates. The increasing role of pharmacies and retail clinics in administering flu shots has further improved vaccine accessibility, particularly in developed regions.

Additionally, the growing global focus on pandemic preparedness has reinforced the importance of influenza vaccination. The COVID-19 pandemic has highlighted the need for robust respiratory disease prevention measures, leading to increased investments in flu vaccine research and development. As healthcare systems prioritize preventive care, the demand for influenza vaccines is expected to rise, shaping the market’s trajectory in the coming years.

SCOPE OF STUDY:

The report analyzes the Influenza Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Vaccine Type (Inactivated, Live attenuated); Indication (Quadrivalent, Trivalent); Technology (Egg-based, Cell-based); Flu Type (Seasonal, Pandemic); Age Group (Pediatrics, Adults)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â